CFM
LXEO icon

Catalyst Funds Management’s Lexeo Therapeutics LXEO Stock Holding History

Catalyst Funds Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-531
Closed -$8.33K – 1411
2024
Q1 		$8.33K Buy
+531
New +$8.3K ﹤0.01% 913

Other funds holding LXEO

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Catalyst Funds Management's LXEO Position: Q2 2024 in Review

Catalyst Funds Management sold out of Lexeo Therapeutics (LXEO) in Q2 2024, closing a stake of 531 shares — an estimated $8.33K sold.

Catalyst Funds Management first reported a position in LXEO in Q1 2024 and held it in 1 quarter. The position peaked at $8.33K in Q1 2024. 59 funds tracked by Wall St. Rank hold LXEO as of Q2 2024.

  • Catalyst Funds Management reported no remaining Lexeo Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 531 Lexeo Therapeutics shares in Q2 2024, an estimated $8.33K.
  • Catalyst Funds Management first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Lexeo Therapeutics position peaked at $8.33K in Q1 2024.
  • 59 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.